Dew, in your post and the news release: "including enoxaparin product revenue of $2.6 million.... Sandoz reported third quarter 2012 enoxaparin net sales of $34 million" I thought MNTA had an 11% royalty now? The above computes to 7.65%. "Excluding the royalty payable to MIT on enoxaparin product..." After deduction of the MIT royalty from the $2.6m revenue, does anybody know the net MNTA had on mLov? Wondering if there is a way that mCop could turn out better than this.